HK Stock Market Move | CF PHARMTECH (02652) rose over 10% intraday; ICF001 covers all four major indications; southbound funds have recently seen continuous net buying.

CF PHARMTECH (02652) moved higher this morning, rising more than 10% at one point intraday. As of press time, it was up 4.25% at HK$10.80, with turnover of HK$26.96 million. On the news front, CF PHARMTECH's self-developed long-acting inhaled dry powder candidate drug ICF001 has recently received multiple clinical trial implied approvals, achieving full coverage of four major indications: PAH, PH-ILD, IPF, and PPF, making it the first company in China to advance this type of long-acting inhaled prodrug to the clinical trial stage in China. It is worth noting that southbound funds have recently seen continuous net buying, with the number of shares held via Stock Connect rising to 24.1592 million shares as of September 11, and the shareholding ratio increasing to 7.45%. The company's Chairman and Executive Director Dr. Liang Wenqing previously stated: "The approval of clinical development for four indications for ICF001 is an important milestone in CF PHARMTECH's transformation from a complex inhalation formulation platform to a global innovative asset. Positive clinical data from similar international drugs have already proven that long-acting inhaled prodrugs can become a next-generation therapeutic direction with global commercial potential."